MX351012B - Neurotoxinas que exhiben actividad biologica acortada. - Google Patents

Neurotoxinas que exhiben actividad biologica acortada.

Info

Publication number
MX351012B
MX351012B MX2014005544A MX2014005544A MX351012B MX 351012 B MX351012 B MX 351012B MX 2014005544 A MX2014005544 A MX 2014005544A MX 2014005544 A MX2014005544 A MX 2014005544A MX 351012 B MX351012 B MX 351012B
Authority
MX
Mexico
Prior art keywords
polypeptides
present
polynucleotide
medicaments
ligase
Prior art date
Application number
MX2014005544A
Other languages
English (en)
Other versions
MX2014005544A (es
Inventor
Schmidt Michael
Frevert Juergen
Hofmann Fred
Groer Gerhard
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48288558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX351012(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2014005544A publication Critical patent/MX2014005544A/es
Publication of MX351012B publication Critical patent/MX351012B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo farmacéutico. Específicamente, contempla un polinucleótido que codifica para un polipéptido de neurotoxina que exhibe una duración reducida del efecto biológico en un sujeto, en donde el polipéptido comprende al menos un motivo de reconocimiento de ligasa E3 de la cadena ligera, en donde el motivo de reconocimiento de ligasa E3 es de preferencia un motivo de unión para la ligasa E3 MDM2. La invención se refiere además a polipéptidos codificados por el polinucleátido de la invención así como a polipéptidos que comprenden una o más sustituciones de aminoácido. La presente invención también abarca vectores y células hospederas que comprenden el polinucleótido, polipéptidos codificados por el mismo y anticuerpos que se unen específicamente a los polipéptidos. Más aún, la invención se refiere a medicamentos que comprenden los polinucleátidos y polipéptidos, así como a aplicaciones terapéuticas específicas de los mismos. Además, la presente invención contempla métodos para la elaboración de los polipéptidos y medicamentos.
MX2014005544A 2011-11-09 2012-11-08 Neurotoxinas que exhiben actividad biologica acortada. MX351012B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161628911P 2011-11-09 2011-11-09
EP11188440 2011-11-09
US201261659137P 2012-06-13 2012-06-13
EP12171801 2012-06-13
PCT/EP2012/072158 WO2013068476A1 (en) 2011-11-09 2012-11-08 Neurotoxins exhibiting shortened biological activity

Publications (2)

Publication Number Publication Date
MX2014005544A MX2014005544A (es) 2014-05-30
MX351012B true MX351012B (es) 2017-09-28

Family

ID=48288558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005544A MX351012B (es) 2011-11-09 2012-11-08 Neurotoxinas que exhiben actividad biologica acortada.

Country Status (18)

Country Link
US (1) US9809809B2 (es)
EP (1) EP2776457B1 (es)
JP (1) JP6162135B2 (es)
KR (1) KR20150000468A (es)
CN (1) CN103974973A (es)
AR (1) AR089655A1 (es)
AU (1) AU2012334080B2 (es)
BR (1) BR112014011137A2 (es)
CA (1) CA2855173A1 (es)
CL (1) CL2014001217A1 (es)
ES (1) ES2638333T3 (es)
HK (1) HK1199890A1 (es)
IL (1) IL232508B (es)
MX (1) MX351012B (es)
RU (1) RU2646110C2 (es)
SG (1) SG11201402131TA (es)
TW (1) TWI583792B (es)
WO (1) WO2013068476A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793934B1 (en) * 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
UA111795C2 (uk) 2012-11-21 2016-06-10 Сінтаксін Лімітед Спосіб виробництва поліпептиду, підданого протеолітичному процесингу
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
EP3154635A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154571A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
WO2015188942A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154562A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3233911B1 (en) 2014-12-19 2020-10-14 Merz Pharma GmbH & Co. KGaA Means and methods for the determination of the biological activity of bont/e in cells
RU2694820C9 (ru) 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
JP6601922B2 (ja) 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
AU2017227978B2 (en) 2016-03-02 2022-03-10 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
CN106432423B (zh) * 2016-09-21 2019-05-10 北京大学深圳研究生院 一种α-螺旋多肽及其用途
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
US11260114B2 (en) 2017-03-22 2022-03-01 Bonti, Inc. Botulinum neurotoxins for use in therapy
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) * 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
US11279734B2 (en) 2017-12-01 2022-03-22 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
WO2019175250A1 (en) * 2018-03-13 2019-09-19 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
CN109666683B (zh) * 2019-02-27 2021-10-29 昆明理工大学 乙酰辅酶A乙酰转移酶基因RKAcaT2及其应用
CN110721314B (zh) * 2019-10-11 2022-11-29 江苏恒泰生物科技有限公司 一种抗肿瘤纳米药物及其制备方法
SE543726C2 (en) * 2020-03-25 2021-06-29 Jonathan Davies Engineered botulinum neurotoxin serotype E
CN111763663B (zh) * 2020-07-09 2022-04-15 昆明理工大学 一种天麻葡糖基转移酶基因及应用
CN112410321B (zh) * 2020-11-26 2022-01-28 昆明理工大学 一种β-葡萄糖苷酶Ttbgl3及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958305B1 (en) * 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
GB9708089D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CA2578250C (en) 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
WO2008106507A2 (en) * 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
WO2009008916A2 (en) * 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
US8486422B2 (en) * 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
FR2924721B1 (fr) * 2007-12-10 2010-02-26 Cytomics Systems Procede de criblage d'agents modulant l'activite de l'ubiquitine ligase mdm2 et moyens destines a la mise en oeuvre dudit procede
US8343743B2 (en) * 2008-06-10 2013-01-01 Synaptic Research, Llc Designer ubiquitin ligases having a non-cleavable SNAP25 domain and E3-ligase domain
US20100278826A1 (en) * 2008-06-10 2010-11-04 Shoemaker Charles B Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity

Also Published As

Publication number Publication date
MX2014005544A (es) 2014-05-30
IL232508B (en) 2018-06-28
CA2855173A1 (en) 2013-05-16
JP6162135B2 (ja) 2017-07-12
AU2012334080A1 (en) 2014-05-15
EP2776457A1 (en) 2014-09-17
AR089655A1 (es) 2014-09-10
RU2014123060A (ru) 2015-12-20
RU2646110C2 (ru) 2018-03-01
US20140308267A1 (en) 2014-10-16
ES2638333T3 (es) 2017-10-19
SG11201402131TA (en) 2014-08-28
KR20150000468A (ko) 2015-01-02
CL2014001217A1 (es) 2014-10-10
EP2776457B1 (en) 2017-08-02
HK1199890A1 (en) 2015-07-24
TWI583792B (zh) 2017-05-21
IL232508A0 (en) 2014-06-30
TW201326390A (zh) 2013-07-01
JP2014533945A (ja) 2014-12-18
BR112014011137A2 (pt) 2018-06-12
US9809809B2 (en) 2017-11-07
WO2013068476A1 (en) 2013-05-16
AU2012334080B2 (en) 2016-12-15
CN103974973A (zh) 2014-08-06

Similar Documents

Publication Publication Date Title
MX351012B (es) Neurotoxinas que exhiben actividad biologica acortada.
MX352265B (es) Neurotoxinas que exhiben actividad biologica acortada.
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
EA201201126A1 (ru) Полипептид, обладающий активностью целлобиогидролазы, и его применение
IN2014DN05670A (es)
IN2014CN00414A (es)
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
EA201300060A1 (ru) Полипептид, обладающий или содействующий активности деградации углеводного материала, и его применение
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
EA201300058A1 (ru) Полипептид, обладающий бета-глюкозидазной активностью, и его применение
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
WO2014172541A3 (en) Engineered phenylalanine ammonia lyase polypeptides
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
EP4276180A3 (en) Clostridium histolyticum enzyme
MX2019009222A (es) Neurotoxinas recombinantes de clostridium botulinum.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
EA201400850A1 (ru) Альфа-амилаза
EA201991059A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
BR112015008673A2 (pt) composto, composição farmacêutica e método
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli

Legal Events

Date Code Title Description
FG Grant or registration